437 results about "Protein level" patented technology

The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of GCase proteins, whether in vitro and / or in vivo. Such compositions include delivery of an adeno-associated viral (AAV) particle. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having Parkinson Disease or related condition resulting from a deficiency in the quantity and / or function of GBA gene product or associated with decreased expression or protein levels of GCase protein.

Disclosed herein are compositions and methods for modulating T cells. For example, the compositions and methods may be used to increase memory T cells. The compositions and methods may increase the expression or protein level of a transcription factor selected from TGIF2LX, TGIF1, TGIF2, FOS, HNF4A, KLF8, NFKBIZ, CARF, EBF3, HMX3, LHX4, LMX1A, PLAG1, PLAGL1, POU2F3, SOX14, TFAP2D, and WT1, or a combination thereof. The compositions and method may be used in combination with Adoptive T Cell Therapy (ACT) to enhance the ACT.

The invention discloses a porcine reproductive and respiratory syndrome virus N protein antigen epitope peptide and a monoclonal antibody thereof. The amino acid sequence of the antigen epitope peptide is as shown in SEQ ID No. 11; the heavy chain variable region of the monoclonal antibody comprises CDR1-3 as shown in SEQ ID No.1 to SEQ ID No.3; the light chain variable region comprises CDR1-3 as shown in SEQ ID No. 4 to 6; the monoclonal antibody reacts with a variety of PRRSV strains such as classical PRRSV, HP-PRRSV, NADC30PRRSV-like, NADC34PRRSV-like, European PRRSV and the like, and the conservative property is good; the antibody can be obtained by biological means such as conventional genetic engineering, and the problem that the genetic sequence of the antibody is easy to lose due to long-term cryopreservation of traditional hybridoma cells is avoided; optimization of the antibody on the gene or protein level is facilitated, and the specificity and affinity of the antibody are further improved.

The preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) NO.33629, the preservation date of the bacterial strain is February 24, 2025, the preservation classification of the bacterial strain is Lactobacillus sakei, and the preservation unit of the bacterial strain is China General Microbiological Culture Collection Center. The strain provided by the invention can reduce the concentration of blood uric acid, relieve kidney inflammation caused by hyperuricemia, improve the protein level of a kidney uric acid excretion channel and reduce the expression level of uric acid resorption protein.

An RNA inhibitor for inhibiting gene expression of a complement system, or a pharmaceutically acceptable salt thereof. The structure of the RNA inhibitor further contains vector structures 5'MVIP and 3'MVIP. The provided RNA inhibitor interferes with the translation template function of the mRNA of the complement system, and continuously and efficiently inhibits the gene expression of the complement system, so that CFB, C5 and C3 protein levels of the complement system in blood are continuously reduced. The RNA inhibitor can be used for treating and / or preventing diseases associated with an increased level of the complement system.

The invention discloses an interfering RNA (Ribonucleic Acid) for inhibiting a PCSK9 gene and application of the interfering RNA. The interfering RNA comprises any one or more than two nucleotide sequences as shown in SEQ ID NO: 1-40 and SEQ ID NO: 73-96. The interfering RNA can better target and silence mRNA of the liver PCSK9, reduce the protein level of the PCSK9, enhance LDL-C metabolism and reduce serum cholesterol, and a solid technical basis is provided for research and development of siRNA drugs for prevention and treatment of PCSK9 gene mediated diseases and symptom relief.

The invention discloses an application of a biomarker in preparation of a kit for a prognosis risk early warning method of an acute ST segment elevation type myocardial infarction patient. The biomarker comprises an HBP (Hepatitis Binding Protein). By monitoring the change of the HBP protein level, whether a patient suffering from the acute ST segment elevation type myocardial infarction has poor prognosis within 30 days after a PCI operation can be effectively evaluated, so that early recognition and timely clinical intervention on high-risk patients are realized, the treatment response speed and effect are improved, the occurrence rate of adverse cardiovascular events is reduced, and the treatment effect of the patient suffering from the acute ST segment elevation type myocardial infarction is improved. And the prognosis of the patient is finally improved.

The invention provides a double-target degradation molecule based on a functionalized nucleic acid connexon and application thereof, and relates to the technical field of biological medicine, the double-target degradation molecule comprises an E3 ubiquitin ligase ligand at one end, a first target protein ligand at the other end, and the functionalized nucleic acid connexon located between the E3 ubiquitin ligase ligand and the first target protein ligand; the functionalized nucleic acid linker is a nucleotide sequence capable of specifically recognizing and combining a second target protein or a coding gene thereof, so that the protein level degradation of the first target protein and the nucleic acid level or expression level inhibition of the second target protein / gene are realized in the same molecule. Functionalized nucleic acid and a PROTAC strategy are organically combined, single-molecule double-target collaborative intervention is achieved, targeting efficiency and treatment potential are improved, higher flexibility and expandability are provided in synthesis and design, and a new molecular platform and technical route are provided for multi-target accurate treatment.

The invention belongs to but is not limited to the technical field of biomedicine, and discloses application of golden amide alcohol ester to preparation of a medicine for treating cholestasis. The in-vitro cell level verifies that the golden amide alcohol ester has relatively strong activity of activating FXR and CAR. The golden amide alcohol ester can relieve the cholestasis symptom of a cholestasis model mouse. The golden amide alcohol ester can obviously reduce the content of total bile acid and bilirubin in cells, relieve cholestasis and relieve hepatocyte damage. The golden amide alcohol ester can regulate and control the protein level of transporters and metabolic enzymes related to bile acid and bilirubin through double excitation of FXR and CAR, relieve cholestasis and achieve the purposes of benefiting gallbladder and removing jaundice.

The invention relates to the technical field of information, and discloses a method for predicting the optimal branched chain amino acid ratio of daily ration of lactating sows, which comprises the following steps of: 1, acquiring production data and feed formula data; 2, processing the production data and the feed formula data to obtain production sample data and formula sample data; 3, performing correlation calculation on the production sample data and the formula sample data to obtain most effective features and calculate feature vectors; 4, training a preset model according to the feature vector and the formula sample data; 5, verifying the preset model, and selecting an optimal prediction model according to an evaluation result; and 6, outputting an isoleucine content prediction value, a leucine content prediction value and a valine content prediction value by the optimal prediction model. The prediction method can accurately and reliably predict the branched chain amino acid proportion of daily ration with different protein levels. Meanwhile, the invention further provides a prediction device for the optimal branched chain amino acid proportion of the daily ration of the lactating sow.

The invention discloses a missense mutation function effect prediction model construction method and a prediction method, and relates to the technical field of biological information. According to the method, on the basis of pathogenic and benign missense mutation data, various molecular phenotypic characteristics are enriched and annotated through statistical indexes, and a machine learning model for mutation function effect prediction is constructed. The model fuses feature information of a plurality of molecular levels, comprises comprehensive evaluation indexes of a residual base level, a mutation level and a protein level, and is trained and optimized based on a random forest algorithm. The method not only can accurately predict pathogenic mutation, but also shows excellent performance in recognition of cancer-driven missense mutation, has good generalization ability and biological interpretability, and can provide solid technical support for pathogenicity and carcinogenicity recognition of missense mutation and molecular mechanism research of missense mutation.

The invention discloses miRNA for regulating and controlling liver carnitine palmitoyl transferase I and application of the miRNA, and belongs to the field of molecular biology. According to the present invention, the existence of the binding site with the miR-380-3p in the CPT1A 3UTR region is clarified; experiments of transfecting miR-380-3p simulants and interferents by fetal sheep kidney medullary cells prove that the expression quantity of the CPT1A gene can be remarkably reduced at mRNA and protein levels through miR-380-3p overexpression, and the expression quantity of the CPT1A gene can be remarkably increased at the protein level through interference of endogenous miR-380-3p. Furthermore, the miR-380-3p provided by the invention can effectively regulate the expression of a target gene CPT1A, so that the miR-380-3p participates in influencing the metabolism of fatty acid, plays an important role in adapting the mongolian sheep to a cold environment in winter, and has application potential in the treatment of human obesity.

The invention provides a traditional Chinese medicine compound for treating sicca syndrome and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compounds. The traditional Chinese medicine compound provided by the invention has the effects of eliminating dampness and heat, removing blood stasis and promoting salivation, can safely and effectively treat sicca syndrome by improving functions of exocrine glands and regulating immunity, belongs to a pure traditional Chinese medicine preparation, and has no toxic or side effect. The traditional Chinese medicine compound is proved to be capable of remarkably relieving the sicca syndrome, relieving dry mouth and eye symptoms of a patient, relieving fatigue, regulating and controlling a plurality of signals taking RAGE / TLR4 as a core, inhibiting excessive activation of an HMGB1-RAGE / TLR4-NF-kappa B pro-inflammatory pathway from gene and protein levels, inhibiting generation of pro-inflammatory cytokines, reducing inflammatory response and improving the immunity of the patient. The effect of treating the sicca syndrome is achieved. By acting on STAT3 phosphorylation, Tfh proliferation is inhibited, IL-21 secretion is reduced, humoral immune disorder is relieved, and the sicca syndrome is treated, so that the condition of the sicca syndrome is relieved, and the prognosis of the sicca syndrome is improved.

The invention relates to the technical field of bioactive peptides, and discloses a walnut peptide with a neuroprotection function and a preparation method and application thereof, and predicts that a batch of small molecular walnut peptides have the neuroprotection function through enzymolysis of natural walnut protein, molecular weight screening and molecular docking. Experiments prove that the walnut peptide disclosed by the invention has a nerve protection function: the cell activity of nerve cells is improved, and the walnut peptide plays a role in preventing neurodegenerative diseases and other nerve-related diseases; the toxic effect of oxidative damage on nerve cells is relieved, nerve cell apoptosis is inhibited, the cell viability of the nerve cells is improved, and the function of treating nerve injury related diseases is achieved; the compound can be used for improving the activity of nerve cells, relieving oxidative damage of the nerve cells, adjusting the protein level of nerve damage related pathways, preparing related drugs for reducing blood pressure or resisting senile dementia or tumors and the like, and has a wide application prospect.

The invention discloses application of an SFRP1 gene in buffalo ovarian granular cells, and belongs to the technical field of cell engineering and gene engineering. According to the invention, SFRP1 is taken as a research object, an SFRP1 overexpression vector or siRNA-SFRP1 is respectively transfected to ovarian granular cells by constructing the SFRP1 overexpression vector and synthesizing small interfering RNA (siRNA-SFRP1), then changes of signal channel gene mRNA and protein level related to ovarian granular cell apoptosis, proliferation and E2 and P4 secretion are detected, and finally phenotypic changes of the ovarian granular cells are detected. Results show that the SFRP1 can inhibit apoptosis of ovarian granular cells and promote proliferation and E2 and P4 secretion. The application of the SFRP1 in the ovarian granular cells is explored, and the SFRP1 has good application in research of an ovarian follicle atresia mechanism, initial estrus initiation and the like.

Methods of treatment with a myosin inhibitor using protein levels; methods of monitoring response to treatment based on such protein levels; and methods of determining whether to treat a patient with a myosin inhibitor based on such protein levels are described herein. Such methods may include obtaining a biological sample of a subject, measuring one or more protein levels in the sample, analyzing the one or more protein levels, and determining the treatment response based on the analysis, and may further include treating the subject based on the determination of treatment response.

The invention belongs to the field of antibodies, and particularly relates to a p-Tau217 phosphorylated protein binding antibody or an antigen binding part thereof and application thereof. The invention provides the amino acid sequences of the heavy chain CDR and the light chain CDR of the antibody specifically bound with the p-Tau217 phosphorylated protein, and the antibody can specifically recognize and bind the p-Tau217 phosphorylated protein and has the advantages of high affinity and good specificity to the protein. Based on the advantages, the antibody can be applied to diagnosis of diseases (such as nervous system degenerative diseases) related to abnormal p-Tau217 phosphorylated protein level, and especially can be applied to clinical diagnosis of Alzheimer's disease.

The invention discloses a DKA combined AP risk prediction model based on multi-index fusion, a medium and equipment, and relates to the technical field of medical health and artificial intelligence, and the risk prediction model comprises a preprocessing unit which is used for carrying out the standardization processing of basic data and clinical data of a diabetic ketoacidosis patient, the clinical data comprises stomachache symptoms, C reactive protein level and serum lipase level; the screening unit is used for screening the basic data according to an exclusion mechanism; the data integration unit is used for obtaining the probability of occurrence of DKA and AP events by combining the following formula according to the screening result: Q = 1 / (1 + e-(beta0 + beta1 * stomachache + beta2 * CRP + beta3 * LPS)); and the output unit is used for outputting the probability calculated by the data integration unit as a result. Under the emergency treatment scene, the risk of acute pancreatitis complicated by the diabetic ketoacidosis patient can be rapidly evaluated, and a good preposed basis is provided for clinical decision making.

The invention belongs to the technical field of medicine, and particularly relates to application of a small molecule compound R406 in preparation of a product for preventing and treating Parkinson's disease, screening based on small molecules and microarrays is carried out, the compound R406 can reduce the alpha-syn protein level in an autophagy-dependent mode, and in addition, the compound R406 can be used for preparing a product for preventing and treating Parkinson's disease. The R406 also reduces the level of alpha-syn phosphorylated serine 129 in a fiber-induced cell model pre-formed by alpha-syn, and prevents neuronal degeneration. In addition, experiments confirm that the R406 can relieve PD-related disease phenotypes in a human alpha-syn preformed fiber-induced cell model and a PD patient-derived organ-like model, and a new thought is provided for treatment of the Parkinson's disease.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of Xianglian intestine decoction in preparation of a medicine for treating ulcerative colitis through a targeted TLR4 / NLRP3 / GSDMD channel. According to the invention, the TLR4 is determined as a key target, and experiments show that the active ingredients in the Xianglian intestine soup and the TLR4 have very strong binding affinity. In-vivo experiments prove that the Xianglian intestine soup down regulates the protein levels of TLR4, NLRP3 and GSDMD-N and the mRNA expression (Plt; 0.05) of IL-1beta and IL-18, so that the pyroptosis is inhibited. Furthermore, the Xianglian intestine decoction inhibits NLRP3 inflammasome activation and GSDMD-mediated pyroptosis by targeting TLR4 so as to relieve UC inflammation and intestinal barrier injury. The invention provides a mechanism insight for the clinical curative effect of the Xianglian intestine decoction for treating ulcerative colitis.

Aspects of the invention provide an AAV product that delivers an STXBP1 gene supplementation or replacement strategy throughout the human CNS at levels of DNA biodistribution, RNA expression, and hSTXBPlb protein levels expected to restore function in STXBP1 encephalopathy patients.

The invention discloses natto oligopeptide capable of relieving formation of arterial plaques and a preparation method and application thereof, belongs to the field of active peptide preparation, aims to solve the problem of obtaining natto or oligopeptide thereof capable of relieving formation of atherosclerotic plaques, and is characterized in that soybeans are soaked, sterilized, inoculated with compound bacteria, fermented at constant temperature and subjected to after-ripening to obtain natto, the volume ratio of the bacillus natto to the lactobacillus plantarum to the bifidobacterium bifidum in the compound bacteria is 1: (0.3-0.5): (0.1-0.3); compound protease is added into the aqueous solution of the freeze-dried natto powder for hydrolysis, centrifugation and filtration, components below 30000 Da are intercepted to obtain the natto oligopeptide, the ratio of chymotrypsin to papain in the compound protease is (1-3): 1, and the natto oligopeptide has the effects that the content of nattokinase in natto is higher, the protein level is also improved, and the natto oligopeptide can be used for preparing the natto oligopeptide. The nattokinase activity is well reserved in hydrolysis, the effect of promoting macrophage autophagy is achieved, and atherosclerotic plaque formation can be relieved.

The invention provides an intelligent optimization method for carbon emission reduction of an ecological pasture in extreme weather, and relates to the technical field of intelligent optimization of carbon emission reduction. Comprising the steps that initial monitoring data are collected and preprocessed, and multi-dimensional feature vector output state features are constructed; an LSTM time sequence prediction model is used for analyzing the state of the dairy cow and the activity of methanogens in the rumen, DHI data of an integrated gradient boosting tree model is used for analyzing the amino acid balance and precise nutrition technology of the lactating dairy cow, a dairy cow manure yield prediction model based on a Bayesian network is constructed, a manure management strategy is dynamically optimized, and manure management effect data is output. And constructing a carbon emission reduction comprehensive evaluation model, and evaluating the pasture carbon emission reduction effect. According to the invention, the rumen flora structure is regulated and controlled, the rumen greenhouse gas emission is controlled, the ruminant feed protein level is reduced, and the methane emission is reduced by researching the dairy cow carbon emission rumen microorganism regulation and control technology.

The invention relates to the technical field of biological medicines, and provides application of ADRM1 gene / protein in preparation of a medicine for treating osteosarcoma. When the ADRM1 gene / protein is applied to the preparation of the medicine for treating osteosarcoma, the proliferation, migration and invasion capabilities of tumor cells can be remarkably inhibited, so that the occurrence and development of osteosarcoma are delayed. The expression of the ADRM1 is knocked down through an shRNA intervention technology, the mRNA and protein level of the ADRM1 in 143b and U2OS osteosarcoma cell lines can be remarkably reduced, the short-term proliferative activity and the long-term clone forming ability of the ADRM1 are further inhibited, and the migration and invasion characteristics of cells are effectively weakened. The growth of a tumor body formed after a nude mouse is inoculated with 143b osteosarcoma cells knocking down ADRM1 is obviously slowed down, and the expression of a cell proliferation marker KI-67 in the tumor body is reduced, which indicates that the ADRM1 gene / protein also plays a key regulation role in the in-vivo growth process of osteosarcoma.

To provide an estimation method for estimating the amount of marker proteins in the stratum corneum. [Solution] Identify one or more cell regions, stratified exfoliation regions, and single-cell regions in the stratum corneum image. A marker protein quantity estimation method that estimates the amount of marker proteins in the stratum corneum from stratum corneum images based on the correlation between the obtained stratum corneum parameters as explanatory variables and one of the following as the dependent variable: Enolase-1 quantity, FABP5 quantity, or Polyamine quantity.

The present invention relates to the treatment of cancer, including colorectal cancer (CRC), by inhibiting or blocking Annexin 1. The present invention also relates to the prevention of CRC in high risk patients by inhibiting or blocking Annexin A1. The present invention also relates to the reduction of chemotherapy resistance by inhibiting or blocking Annexin A1. The present invention also relates to the detection of poor prognosis in subjects with CRC by detecting or measuring the expression level of ANXA1 and / or the protein level of Annexin 1.

The invention provides an application technology for screening lung cancer high-risk groups, early auxiliary diagnosis and postoperative treatment effect monitoring of lung cancer patients through model and computing power, and belongs to the fields of molecular biotechnology, medical diagnosis and treatment and massive health. The method comprises the following steps: collecting samples of human body liquid, exosomes and the like, detecting the DNA methylation level, miRNA expression quantity, protein level and the quantity of molecular markers such as autoantibodies, exosomes, kits and the like related to the lung cancer by virtue of a modern detection technology, and obtaining individual precision medical treatment and clinical application by virtue of a model and computing power (including a software algorithm, a DeepSeek large model, intelligent agent application and an artificial intelligence method). The problems of lung cancer high-risk group screening, early auxiliary diagnosis, pathological typing, clinical staging, metastatic state, postoperative curative effect evaluation and poor accuracy of national approved kits are solved. The non-destructive detection technology can prevent and treat lung cancer in time, is precise in medical treatment and good in health prevention, and has wide social benefits and popularization and use values. The traditional Chinese medicine composition also has a popularization effect on other non-lung cancers.

The invention belongs to the technical field of biology, and particularly relates to application of carboplatin in preparation of a medicine for preventing and / or treating negative chain RNA virus infection. Experimental results show that the carboplatin has no obvious influence on the cell survival rate, and the virus titer in the Vero cells treated by the carboplatin is obviously reduced; the replication of PPRV in Vero cells can be significantly inhibited, and the inhibition effect is most significant when the concentration of carboplatin is 100 [mu] M; and the N protein level in Vero cells treated by carboplatin (100 [mu] M) is remarkably reduced, so that the method has a wide application prospect.

The invention belongs to the technical field of biological medicine, and particularly provides application of flufenidone in preparation of a medicine for preventing or treating left heart failure. The research finds that the flufenidone has the effects of relieving myocardial cell hypertrophy under a heart failure cell model and relieving myocardial hypertrophy, fibrosis and heart function deterioration of an aortic constriction animal model. According to the present invention, further research results show that fluorofenidone is directly combined with SERCA2a through Q758, D812 and E917 residues of SERCA2a so as to inhibit recognition, combination and polyubiquitination effects of WWP1 on SERCA2a, such that the protein level and the activity of SERCA2a are stabilized so as to achieve the chronic left heart failure treatment purpose. Therefore, the flufenidone serving as an active ingredient has good application prospect and application value in research and development of novel medicines for treating chronic left heart failure.

Disclosed herein are cell compositions with increased expression of 11S proteasomal cap proteins. The cell compositions provided herein result in increased heterologous protein levels. As such, the cell compositions may be used in methods for increasing protein production of one or more heterologous proteins, including but not limited to proteins relevant for cell and gene therapy.